Zyprexa news | Breaking Zyprexa news | Zyprexa

Better Pipelines Could Boost Big Pharma

...Much the same is true of Schering-Plough (nyse: SGP - news - people ), which is heavily dependent on Vytorin, a cholesterol drug.He sees Merck (nyse: MRK - news - people ) dipping in the near term to $32 per share, as $20 billion in potential Vioxx litigation costs continue to linger.More On This Topic Companies: PFE MRK -% String xsl=(String) application.getAttribute(com.forbes.cms.Constants.XSL_REP_KEY)+"/story_body_html_trans.xsl"; final TransformerFactory tFactory = TransformerFactory.newInstance(); final Transformer transformer = tFactory.newTransformer(new StreamSource(xsl)); final ByteArrayOutputStream bao = new ByteArrayOutputStream(); byte[] bytes = transformedStoryStr.getBytes(); ByteArrayInputStream input=new ByteArrayInputStream(bytes); InputStream myInput=(InputStream)input; try{ transformer.transform(new StreamSource(myInput), new StreamResult(bao)); }catch (Exception e){ e.printStackTrace(); } transformedStoryStr=bao.toString(); // System.out.println(...

BITTER PILL ; It's Hard for the Drug Companies to Swallow, but ...

... IN HEALTH Health Home © International News Service 1999 - 2006 Reuse Permissions Hosted by Zanyspace ...

Lilly says hands off Gemzar

...An appeal is scheduled for oral argument next month before the U.S.

Court of Appeals in Washington, D.C.Analyst Zach Wagner believes Lilly has little to worry about with the Wagner, who covers Lilly for St.

Louis-based Edward Jones, said patent challenges have become common for any successful pharmaceutical product."Challenges are common, but successful ones are pretty rare," he said.Standard & Poor's analyst Herman Saftlas agreed.

He said it takes a while for Wall Street to become concerned over patent litigation."Until there's an official trial date, I don't think anyone starts to worry about these things," he said.

Even so, Lilly's patent-defense record sports a big blemish.

The company lost patent protection in 2000 for its then-best seller, Prozac, during an appeal.Lilly introduced Gemzar to the U.S.

market in 1996 as a treatment for advanced pancreatic cancer.

It has since received approval for treatment, in combination with other drugs, of non-small-cell lung cancer and advanced breast cancer.Gemzar ranked fifth among Lilly drugs with $586 million in domestic sales in 2005.

The drug rang up $1.3 billion worldwide last year, second in Lilly's product portfolio only to While

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news

Medicine   Health and Fitness